recist and irecist criteria for the evaluation of nivolumab ipilimumab in msi/dmmr mcrc
Published 3 years ago • 658 plays • Length 1:41Download video MP4
Download video MP3
Similar videos
-
1:11
nivolumab/ipilimumab combination data promising in msi-h/dmmr mcrc
-
5:10
checkmate 214: patterns of progression with nivolumab plus ipilimumab versus sunitinib for rcc
-
7:18
who is the appropriate rcc patient to receive combination ipilimumab/nivolumab?
-
5:19
fraction-rcc: evaluating nivolumab plus ipilimumab in patients with treatment-refractory advance...
-
5:44
hcrn-gu16-260: nivolumab and salvage nivolumab-ipilimumab in patients with advanced rcc
-
10:22
dr. karasic on phase ii trial of nivolumab and ipilimumab
-
7:05
recist 1.0 and 1.1: overview and data challenges in oncology clinical trials trailer
-
1:08
dr. motzer on nivolumab/ipilimumab activity in rcc
-
10:36
work day in my life as a medical device engineer
-
49:31
response evaluation criteria in solid tumors (recorded live)
-
8:02
april trial: aptoll demonstrates neuroprotective effects in acute ischemic stroke
-
2:09
checkmate 032: nivolumab/ipilimumab for urothelial carcinoma
-
4:58
long-term results from checkmate 040: nivolumab ipilimumab in advanced hcc
-
1:55
neoadjuvant ipilimumab plus nivolumab in stage iii melanoma
-
2:55
determining the prognosis of patients with myelodysplastic syndromes using machine learning
-
25:25
resisting recist- new methods of assessing tumour response to therapy, r gore
-
29:27
developing a testing plan for medical device design verification
-
4:41
anthartic trial
-
6:26
recist 1.0 and 1.1: overview and data challenges in oncology clinical trials trailer
-
20:05
recist 1.1 crash course
-
1:54
checkmate 214 trial in rcc updates
-
18:21
decisional tools to determine need for biopsy and re-biopsy in men with elevated psas